Spero R. Cataland

6.8k total citations · 1 hit paper
113 papers, 3.7k citations indexed

About

Spero R. Cataland is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Spero R. Cataland has authored 113 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Immunology, 52 papers in Hematology and 48 papers in Genetics. Recurrent topics in Spero R. Cataland's work include Complement system in diseases (89 papers), Renal Diseases and Glomerulopathies (40 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (35 papers). Spero R. Cataland is often cited by papers focused on Complement system in diseases (89 papers), Renal Diseases and Glomerulopathies (40 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (35 papers). Spero R. Cataland collaborates with scholars based in United States, United Kingdom and France. Spero R. Cataland's co-authors include Haifeng Wu, Flora Peyvandi, Paul Coppo, Marie Scully, Johanna A. Kremer Hovinga, Javier de la Rubia, Katerina Pavenski, Filip Callewaert, Hilde De Winter and Camila Masias and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Spero R. Cataland

103 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

2019 602 citations Marie Scully, Spero R. Cataland et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Spero R. Cataland United States	33	2.7k	1.7k	1.4k	1.0k	415	113	3.7k
Yahsou Delmas France	27	1.8k 0.7×	778 0.5×	1.5k 1.1×	664 0.6×	418 1.0×	78	3.0k
Anita Hill United Kingdom	23	2.7k 1.0×	2.2k 1.3×	1.4k 1.0×	1.2k 1.1×	178 0.4×	54	4.2k
Marie‐Agnès Dragon‐Durey France	39	4.8k 1.8×	2.3k 1.3×	3.3k 2.4×	742 0.7×	424 1.0×	100	5.7k
Petra Muus Netherlands	37	2.6k 0.9×	3.3k 1.9×	1.4k 1.0×	1.4k 1.3×	1.2k 2.8×	176	5.8k
Han‐Mou Tsai United States	32	4.4k 1.6×	3.2k 1.9×	2.1k 1.5×	1.5k 1.5×	270 0.7×	72	5.6k
Paul Browne Ireland	26	1.5k 0.5×	1.3k 0.8×	678 0.5×	956 0.9×	858 2.1×	68	3.7k
Austin Kulasekararaj United Kingdom	35	2.1k 0.8×	3.3k 2.0×	873 0.6×	1.5k 1.5×	880 2.1×	207	5.1k
Camille L. Bedrosian United States	23	1.4k 0.5×	867 0.5×	861 0.6×	456 0.4×	732 1.8×	77	2.8k
Leticia Nolasco United States	25	2.2k 0.8×	2.4k 1.5×	707 0.5×	653 0.6×	248 0.6×	38	3.7k
Max Solenthaler Switzerland	14	2.0k 0.8×	1.6k 1.0×	990 0.7×	808 0.8×	225 0.5×	29	2.7k

Countries citing papers authored by Spero R. Cataland

Since Specialization

Citations

This map shows the geographic impact of Spero R. Cataland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Spero R. Cataland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Spero R. Cataland more than expected).

Fields of papers citing papers by Spero R. Cataland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Spero R. Cataland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Spero R. Cataland. The network helps show where Spero R. Cataland may publish in the future.

Co-authorship network of co-authors of Spero R. Cataland

This figure shows the co-authorship network connecting the top 25 collaborators of Spero R. Cataland. A scholar is included among the top collaborators of Spero R. Cataland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Spero R. Cataland. Spero R. Cataland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scully, Marie, Spero R. Cataland, Paul Coppo, et al.. (2025). Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial. Blood. 146(Supplement 1). 849–849.

Cataland, Spero R.. (2024). Not So BenignThis Is Not Your Father’s Thrombotic Thrombocytopenic Purpura. The Hematologist. 21(3). 2 indexed citations

Farid, Saira, et al.. (2023). Thrombotic Complications in Immune Thrombocytopenia Patients Treated with Avatrombopag. SHILAP Revista de lepidopterología. 15(3). 518–523. 1 indexed citations

Scully, Marie, Jerzy Windyga, Björn Mellgård, et al.. (2023). OC 14.1 Phase 3 Prospective, Randomized, Controlled, Open-Label, Multicenter, Crossover Study of Recombinant ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura. Research and Practice in Thrombosis and Haemostasis. 7. 100533–100533. 3 indexed citations

Coppo, Paul, Parth Patwari, Björn Mellgård, et al.. (2023). OC 14.4 Recombinant ADAMTS13 Prophylaxis in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Analysis from Phase 3B Continuation Study. Research and Practice in Thrombosis and Haemostasis. 7. 100534–100534. 2 indexed citations

Sukumar, Senthil, et al.. (2023). Thrombotic Thrombocytopenic Purpura (TTP) Survivors Exhibit Impaired Stress Perfusion on Cardiac MRI. Blood. 142(Supplement 1). 696–696. 1 indexed citations

Scully, Marie, Jovanna Baptista, Spero R. Cataland, et al.. (2023). S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA. HemaSphere. 7(S3). e8651306–e8651306. 6 indexed citations

Scully, Marie, Javier de la Rubia, Ara Metjian, et al.. (2022). Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study. Journal of Thrombosis and Haemostasis. 20(12). 2810–2822. 14 indexed citations

Peyvandi, Flora, Spero R. Cataland, Marie Scully, et al.. (2021). INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA. Hematology Transfusion and Cell Therapy. 43. S46–S47.

10.

Peyvandi, Flora, Spero R. Cataland, Marie Scully, et al.. (2021). Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances. 5(8). 2137–2141. 50 indexed citations

11.

Cuker, Adam, Spero R. Cataland, Paul Coppo, et al.. (2021). Redefining outcomes in immune TTP: an international working group consensus report. Blood. 137(14). 1855–1861. 121 indexed citations

12.

Zheng, X. Long, Sara K. Vesely, Spero R. Cataland, et al.. (2020). ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 18(10). 2496–2502. 208 indexed citations

13.

Terrell, Deirdra R., Spero R. Cataland, Laura A. Beebe, et al.. (2019). Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. Blood. 134(Supplement_1). 931–931. 3 indexed citations

14.

Cataland, Spero R., Marie Scully, Flora Peyvandi, et al.. (2019). Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood. 134(Supplement_1). 4908–4908.

15.

Chaturvedi, Shruti, Olalekan O. Oluwole, Spero R. Cataland, & Keith R. McCrae. (2017). Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thrombosis Research. 151. 51–56. 32 indexed citations

16.

Chen, Jian, et al.. (2017). Increased complement activation during platelet storage. Transfusion. 57(9). 2182–2188. 20 indexed citations

17.

Cataland, Spero R. & Haifeng Wu. (2014). Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews. 28(2). 67–74. 35 indexed citations

18.

Jin, Ming, T. Charles Casper, Spero R. Cataland, et al.. (2008). Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. British Journal of Haematology. 141(5). 651–658. 98 indexed citations

19.

Jin, Ming, Spero R. Cataland, M.G. Bissell, & Haifeng Wu. (2006). A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time‐of‐flight (SELDI‐TOF)‐mass spectrometry. Journal of Thrombosis and Haemostasis. 4(2). 333–338. 56 indexed citations

20.

Cataland, Spero R. & Haifeng Wu. (2005). Immunotherapy for thrombotic thrombocytopenic purpura. Current Opinion in Hematology. 12(5). 359–363. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact